Paul Matteis is ranked #204 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

STIF

Paul Matteis

Q: How accurate are Paul Matteis's stock ratings?

About 68% of Paul's ratings were profitable over a one-year hold, with an average return of +18.8% per rating, measured by 13Foresight from historical prices.

Stifel Nicolaus

Wall Street Analyst

★★★★★

#204

on 13Foresight · ranked by our own returns

71%

Success Rate

+26.1%

Average Return

51 of 72 calls profitable · +17.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 71% of Paul Matteis's ratings turned a profit when each position was held for 2 year — averaging +26.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

131 Buy 39 Hold 0 Sell

Paul's Stock Coverage 41 ratings · 2026-08-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
SION Sionna Therapeutics, Inc.	Aug 10, 2026	HOLD	Hold +159.8% avg upside 12 analysts	$7.00 12.00% Upside	+45.3%	·
VRTX Vertex Pharmaceuticals	Aug 09, 2026	HOLD	Strong Buy -15.5% avg upside 62 analysts	$500.00 4.96% Downside	+0.4%	·
BMRN BioMarin Pharmaceutical	Aug 07, 2026	HOLD	Strong Buy +35.2% avg upside 52 analysts	$70.00 0.28% Downside	+8.4%	·
DNLI Denali Therapeutics	Aug 07, 2026	BUY	Strong Buy +52.6% avg upside 24 analysts	$41.00 62.33% Upside	+1.6%	·
DFTX Definium Therapeutics	Aug 07, 2026	BUY	Strong Buy +15.8% avg upside 21 analysts	$60.00 40.21% Upside	-5.1%	·
XENE Xenon	Aug 07, 2026	BUY	Strong Buy -4.0% avg upside 28 analysts	$86.00 31.87% Upside	+1.4%	·
GHRS GH Research	Aug 06, 2026	BUY	Strong Buy +31.2% avg upside 12 analysts	$38.00 25.63% Upside	-2.1%	·
ACAD ACADIA Pharmaceuticals	Aug 05, 2026	HOLD	Strong Buy +24.3% avg upside 43 analysts	$25.00 15.15% Downside	-1.5%	·
IONS Ionis Pharmaceuticals	Aug 02, 2026	HOLD	Strong Buy +40.4% avg upside 43 analysts	$68.00 20.23% Upside	+4.5%	·
BIIB Biogen	Aug 02, 2026	BUY	Strong Buy +21.4% avg upside 52 analysts	$242.00 15.89% Upside	+3.5%	·
NBIX Neurocrine	Jul 31, 2026	BUY	Strong Buy +19.2% avg upside 37 analysts	$215.00 37.34% Upside	-6.2%	·
DYN Dyne Therapeutics	Jul 31, 2026	BUY	Strong Buy +51.5% avg upside 31 analysts	$37.00 41.43% Upside	+3.1%	·
ALNY Alnylam Pharma	Jul 31, 2026	BUY	Strong Buy +44.8% avg upside 51 analysts	$318.00 42.07% Upside	+10.5%	·
ALKS Alkermes	Jul 25, 2026	BUY	Strong Buy -17.2% avg upside 34 analysts	$63.00 25.25% Upside	-6.9%	·
CMPS COMPASS Pathways	Jul 08, 2026	BUY	Strong Buy +57.6% avg upside 20 analysts	$21.00 47.61% Upside	-2.4%	·
VTGN VistaGen Therapeutics	Jul 06, 2026	HOLD	Hold +901.4% avg upside 8 analysts	$1.00 282.77% Upside	+12.0%	·
LXEO Lexeo Therapeutics, Inc.	Jul 06, 2026	BUY	Strong Buy +295.1% avg upside 11 analysts	$17.00 249.06% Upside	+7.8%	·
NGNE Neurogene	Jul 06, 2026	BUY	Strong Buy +32.6% avg upside 23 analysts	$46.00 24.49% Upside	+9.6%	·
QURE uniQure	Jun 21, 2026	BUY	Strong Buy +31.0% avg upside 29 analysts	$71.00 57.29% Upside	+5.1%	·
RYTM Rhythm Pharmaceuticals	Jun 15, 2026	BUY	Strong Buy +7.1% avg upside 20 analysts	$133.00 13.06% Upside	+29.3%	·
SPTX Seaport Therapeutics, Inc.	Jun 09, 2026	BUY	Strong Buy +61.5% avg upside 6 analysts	$30.00 26.12% Upside	+33.8%	·
MPLT MapLight Therapeutics, Inc.	Jun 02, 2026	BUY	Strong Buy +157.5% avg upside 13 analysts	$36.00 216.29% Upside	-57.6%	·
IMUX Immunic	May 28, 2026	BUY	Strong Buy +144.1% avg upside 21 analysts	$25.00 56.90% Upside	+9.9%	·
RAPP Rapport Therapeutics, Inc.	May 12, 2026	BUY	Strong Buy +20.3% avg upside 14 analysts	$56.00 17.40% Upside	+27.6%	·
NMRA Neumora Therapeutics, Inc.	May 12, 2026	HOLD	Buy +350.0% avg upside 11 analysts	$3.00 75.46% Upside	-8.9%	·
CTNM Contineum Therapeutics, Inc. Class A	May 08, 2026	BUY	Strong Buy +45.6% avg upside 9 analysts	$28.00 86.93% Upside	+10.5%	·
PEPG PepGen Inc.	Apr 04, 2026	BUY	Strong Buy +265.4% avg upside 9 analysts	$12.00 313.73% Upside	+53.8%	·
ANRO Alto Neuroscience, Inc.	Apr 02, 2026	BUY	Strong Buy +4.2% avg upside 13 analysts	$33.00 13.02% Upside	+49.0%	·
LBRX LB Pharmaceuticals, Inc.	Mar 27, 2026	BUY	Strong Buy +1.7% avg upside 8 analysts	$40.00 11.76% Downside	+85.7%	·
ALEC Alector	Dec 22, 2025	HOLD	Hold +364.1% avg upside 14 analysts	—	+40.7%	·
ABOS Acumen Pharmaceuticals	Dec 16, 2025	BUY	Strong Buy +222.9% avg upside 10 analysts	$10.00 298.46% Upside	+17.1%	·
LONA LeonaBio	Sep 19, 2024	HOLD	Buy +42.7% avg upside 9 analysts	—	+69.2%	·
CLYM Climb Bio	Jun 03, 2023	BUY	Strong Buy +33.3% avg upside 19 analysts	$5.00 65.23% Downside	-56.3%	·
WVE Wave Life Sciences	May 12, 2022	HOLD	Strong Buy +299.0% avg upside 28 analysts	$3.00 42.79% Downside	+335.7%	·
IRON Disc Medicine	Feb 28, 2022	HOLD	Strong Buy +7.6% avg upside 21 analysts	$20.00 75.20% Downside	+59.7%	·
OBSEF ObsEva	Aug 16, 2017	BUY	Buy +10799900.0% avg upside 8 analysts	$18.00 17999899.99% Upside	·	·
NBRVF Nabriva Therapeutics	Mar 10, 2017	BUY	Buy +13374900.0% avg upside 9 analysts	$20.00 19999899.93% Upside	·	·
ACIU AC Immune SA	Nov 23, 2016	BUY	Strong Buy +206.6% avg upside 5 analysts	—	-6.4%	·
FATE Fate Therapeutics	Jun 20, 2016	BUY	Buy +341.7% avg upside 31 analysts	—	+574.0%	·
TBPH Theravance Biopharma	Jun 20, 2016	BUY	Buy +9.0% avg upside 18 analysts	$29.00 71.32% Upside	+8.0%	·
TPST Tempest Therapeutics	May 06, 2016	HOLD	Buy +1711.4% avg upside 18 analysts	$7.00 478.43% Upside	·	·

🔒 36 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Paul Matteis — Frequently Asked Questions

How accurate are Paul Matteis's stock ratings?

Based on the calls 13Foresight could measure, about 68% of Paul's ratings were profitable over a one-year hold, with an average return of +18.8% per rating, or +12.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Paul ranked on 13Foresight?

Paul Matteis is currently ranked #204 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Paul cover?

Paul most recently has ratings on SION, VRTX, BMRN, DNLI, DFTX, XENE, GHRS, ACAD, IONS, BIIB, NBIX, DYN and 29 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Paul Matteis

Rating Distribution

Welcome to 13Foresight!